NFKB1 and acute lymphoblastic leukemia: Finally, QC inhibited constitutive NF-κB activation in the resistant ALL cells when combined with AraC, similar to the effect of BAY11-7082, an NF-κB inhibitor47, as determined by both flow cytometry (Fig. 5E) and immunoblotting (Fig. 5F).